Abingdon-based femtech Verso Biosense, which last year raised £3.9 million in its clinical stage financing round under its previous name of Vivoplex, has signed a second product collaboration agreement with one of the UK’s leading fertility clinics, London Women’s Clinic.
London Women’s Clinic will collaborate with Verso, using its uterine monitoring device to refine the technology and biosensing platform to meet the needs of its fertility patients. Verso’s platform captures critical in-vivo, biosensing data for optimisation and personalisation of IVF treatment, providing helping clinicians and patients make better informed decisions.
The London Women’s Clinic provides world-class fertility care to women and couples across England and Wales. Since it was established in 1985 in Harley Street, it has pioneered many of the routine techniques used to treat fertility today. London Women’s Clinic has regional centres in the South East, North East, and West of England (Bristol) and Wales.
Joseph Cefai, Head of Product Development at Verso Biosense, said:“We are delighted to announce our partnership with the London Women’s Clinic, a true leader in providing world-class fertility treatment to women and couples. It is testament to the potential of our ground-breaking platform that this is the second partnership we have announced in the space of a few of weeks, following our agreement with Homerton University Hospital in March. We are moving at pace to provide our monitoring platform to meet the needs of patients and we are delighted by the progress that we are making.”